Targets › GABA
6 programs from 6 companies in 7 trials: 3 Phase 3, 2 Phase 2, 1 Phase 1, 1 Phase 4; Psychiatry, Neurology, Other; next expected readout Jun 2027.
Open in Phaseline: the race on GABA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sherief Abd-Elsalam | GABA (Gamma amino butyric acid) GABA receptor agonist | GABA | Phase 4 | Epilepsy | Dec 2028 |
| Neurona Therapeutics | NRTX-1001 GABA-secreting GABAergic interneurons derived from human embryonic stem cells | GABA | Phase 3 | Mesial Temporal Lobe Epilepsy; Epilepsy, Temporal Lobe | Jun 2027 |
| PleoPharma | PP-01 Cannabinoid-1 (CB1) partial agonist / GABAergic modulator | CNR1, GABA | Phase 3 | Cannabis Withdrawal | Jun 2027 |
| Beth Israel Deaconess Medical Center | Tiagabine GABA reuptake inhibitor | GABA | Phase 3 | Schizophrenia | – |
| Aelis Farma | AEF0217 GABA-positive allosteric modulator (GABAergic steroid) | GABA | Phase 2 | Down Syndrome (Trisomy 21) | Dec 2027 |
| University of California, San Diego | Phentermine-Topiramate Sympathomimetic amine and gamma-aminobutyric acid modulator for weight loss | HTR2C, GABA | Phase 2 | Colitis, Ulcerative | – |
Schizophrenia (1) Cannabis Withdrawal (1) Mesial Temporal Lobe Epilepsy (1) Epilepsy, Temporal Lobe (1) Epilepsy (1) Down Syndrome (Trisomy 21) (1) Colitis, Ulcerative (1)
small molecule (5), protein or peptide (1)
Beth Israel Deaconess Medical Center (1) PleoPharma (1) Neurona Therapeutics (1) Sherief Abd-Elsalam (1) Aelis Farma (1) University of California, San Diego (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.